Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors

Nancy J. Anderson, Eileen Hacker

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intra-peritoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian cancer. Fatigue may occur as a result of the disease process, treatment, or a wide variety of physical, psychological, or situational factors. Fatigue is one of the most common and distressing side effects associated with chemotherapy and it may be intensifed in women receiving IP chemotherapy. The purpose of this article is to examine fatigue in women receiving IP chemotherapy for advanced ovarian cancer and to examine what aspects of IP chemotherapy may contribute to fatigue development. Factors reviewed include surgery for debulking the tumor and placement of the IP catheter, administration of IV chemotherapy in addition to IP chemotherapy, pain, anemia, sleep disturbances, gastrointestinal disturbances, and emotional distress. Oncology nurses who are knowledgeable about the factors that contribute to fatigue in women receiving IP chemotherapy will be better prepared to conduct a comprehensive assessment and develop effective treatment strategies.

Original languageEnglish (US)
Pages (from-to)445-454
Number of pages10
JournalClinical Journal of Oncology Nursing
Volume12
Issue number3
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Fatigue
Drug Therapy
Peritoneal Cavity
Anemia
Sleep
Therapeutics
Catheters
Nurses
Psychology
Pain

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors. / Anderson, Nancy J.; Hacker, Eileen.

In: Clinical Journal of Oncology Nursing, Vol. 12, No. 3, 01.06.2008, p. 445-454.

Research output: Contribution to journalReview article

@article{fdcf0532c1034fac94fb51b9cb3cdade,
title = "Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors",
abstract = "Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intra-peritoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian cancer. Fatigue may occur as a result of the disease process, treatment, or a wide variety of physical, psychological, or situational factors. Fatigue is one of the most common and distressing side effects associated with chemotherapy and it may be intensifed in women receiving IP chemotherapy. The purpose of this article is to examine fatigue in women receiving IP chemotherapy for advanced ovarian cancer and to examine what aspects of IP chemotherapy may contribute to fatigue development. Factors reviewed include surgery for debulking the tumor and placement of the IP catheter, administration of IV chemotherapy in addition to IP chemotherapy, pain, anemia, sleep disturbances, gastrointestinal disturbances, and emotional distress. Oncology nurses who are knowledgeable about the factors that contribute to fatigue in women receiving IP chemotherapy will be better prepared to conduct a comprehensive assessment and develop effective treatment strategies.",
author = "Anderson, {Nancy J.} and Eileen Hacker",
year = "2008",
month = "6",
day = "1",
doi = "10.1188/08.CJON.445-454",
language = "English (US)",
volume = "12",
pages = "445--454",
journal = "Clinical Journal of Oncology Nursing",
issn = "1092-1095",
publisher = "Oncology Nursing Society",
number = "3",

}

TY - JOUR

T1 - Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors

AU - Anderson, Nancy J.

AU - Hacker, Eileen

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intra-peritoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian cancer. Fatigue may occur as a result of the disease process, treatment, or a wide variety of physical, psychological, or situational factors. Fatigue is one of the most common and distressing side effects associated with chemotherapy and it may be intensifed in women receiving IP chemotherapy. The purpose of this article is to examine fatigue in women receiving IP chemotherapy for advanced ovarian cancer and to examine what aspects of IP chemotherapy may contribute to fatigue development. Factors reviewed include surgery for debulking the tumor and placement of the IP catheter, administration of IV chemotherapy in addition to IP chemotherapy, pain, anemia, sleep disturbances, gastrointestinal disturbances, and emotional distress. Oncology nurses who are knowledgeable about the factors that contribute to fatigue in women receiving IP chemotherapy will be better prepared to conduct a comprehensive assessment and develop effective treatment strategies.

AB - Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intra-peritoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian cancer. Fatigue may occur as a result of the disease process, treatment, or a wide variety of physical, psychological, or situational factors. Fatigue is one of the most common and distressing side effects associated with chemotherapy and it may be intensifed in women receiving IP chemotherapy. The purpose of this article is to examine fatigue in women receiving IP chemotherapy for advanced ovarian cancer and to examine what aspects of IP chemotherapy may contribute to fatigue development. Factors reviewed include surgery for debulking the tumor and placement of the IP catheter, administration of IV chemotherapy in addition to IP chemotherapy, pain, anemia, sleep disturbances, gastrointestinal disturbances, and emotional distress. Oncology nurses who are knowledgeable about the factors that contribute to fatigue in women receiving IP chemotherapy will be better prepared to conduct a comprehensive assessment and develop effective treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=49849085054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849085054&partnerID=8YFLogxK

U2 - 10.1188/08.CJON.445-454

DO - 10.1188/08.CJON.445-454

M3 - Review article

C2 - 18515243

AN - SCOPUS:49849085054

VL - 12

SP - 445

EP - 454

JO - Clinical Journal of Oncology Nursing

JF - Clinical Journal of Oncology Nursing

SN - 1092-1095

IS - 3

ER -